<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37573" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fluticasone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Remien</surname>
            <given-names>Kailey</given-names>
          </name>
          <aff>Akron Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bowman</surname>
            <given-names>Andy</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kailey Remien declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andy Bowman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37573.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fluticasone is a potent corticosteroid that is available as a pivotal therapeutic option in the management of various respiratory and dermatological conditions.&#x000a0;Fluticasone's efficacy extends across asthma, allergic rhinitis, emphysema, and atopic dermatitis, marking it as a versatile agent within the pharmacological arsenal. This&#x000a0;activity elucidates the indications, mechanism of action, adverse events, and contraindications of fluticasone, catering to the diverse needs of healthcare professionals navigating the complexities of patient care.</p>
        <p>The evolution of fluticasone's therapeutic landscape underscores its significance in contemporary medical practice. Recent advancements, including the Food and Drug Administration's approvals for over-the-counter use in hay fever and the novel drug-device combination for chronic rhinosinusitis, exemplify its continued relevance in addressing unmet clinical needs. By embracing evidence-based education and staying abreast of emerging developments, healthcare professionals&#x000a0;can administer fluticasone therapy effectively. This&#x000a0;activity endeavors to enhance patient outcomes by fostering a culture of continuous learning and informed decision-making, thereby reaffirming fluticasone's pivotal role in optimizing therapeutic interventions across diverse clinical scenarios.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fluticasone.</p></list-item><list-item><p>Assess&#x000a0;the potential adverse effects of fluticasone.</p></list-item><list-item><p>Determine&#x000a0;appropriate monitoring for patients using fluticasone.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from fluticasone.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37573&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37573">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37573.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Food and Drug Administration-Approved Indications</bold>
</p>
        <p>Fluticasone is a corticosteroid that can be given via oral, nasal, or topical routes. The route of administration depends on the patient&#x02019;s diagnosis. Oral fluticasone is Food and Drug Administration (FDA)-approved to treat asthma and has an off-label use for chronic obstructive lung disease (COPD) and eosinophilic esophagitis. Inhaled steroids slightly improve lung function and improve COPD symptoms but do not affect the rate of lung function decline.<xref ref-type="bibr" rid="article-37573.r1">[1]</xref> Inhaled fluticasone is FDA-approved as a maintenance/controller drug in asthma. The Global Initiative for Asthma endorses using fluticasone for asthma&#x000a0;(GINA) guidelines.<xref ref-type="bibr" rid="article-37573.r2">[2]</xref>&#x000a0;Nasal fluticasone is FDA-approved for allergic and non-allergic rhinitis and chronic rhinosinusitis with nasal polyps.<xref ref-type="bibr" rid="article-37573.r3">[3]</xref><xref ref-type="bibr" rid="article-37573.r4">[4]</xref>&#x000a0;The topical route&#x000a0;is used for atopic dermatitis and corticosteroid-responsive&#x000a0;dermatoses.<xref ref-type="bibr" rid="article-37573.r5">[5]</xref></p>
        <p>In 2016, fluticasone received Food and Drug Administration (FDA) approval as an over-the-counter medication (a 50 &#x003bc;g spray) for hay fever and upper respiratory allergy symptoms in adults and children&#x000a0;older than&#x000a0;4 years.&#x000a0;Fluticasone is&#x000a0;also approved and available in a fixed-dose combination with azelastine for&#x000a0;allergic rhinitis.<xref ref-type="bibr" rid="article-37573.r6">[6]</xref><xref ref-type="bibr" rid="article-37573.r7">[7]</xref>&#x000a0;In 2024, the FDA expanded the approval of fluticasone propionate nasal spray for chronic rhinosinusitis without nasal polyps (prescription). The novel drug-device combination product utilizes the exhalation delivery system (EDS).<xref ref-type="bibr" rid="article-37573.r8">[8]</xref>&#x000a0;This mechanism facilitates the targeted delivery of fluticasone to the sinonasal regions above the inferior turbinate, with a particular emphasis on reaching sinus drainage pathways typically inaccessible to standard-delivery nasal sprays. This addresses the therapeutic needs of many patients with chronic rhinosinusitis, particularly those without nasal polyps, who may not respond adequately to conventional treatments.<xref ref-type="bibr" rid="article-37573.r8">[8]</xref></p>
      </sec>
      <sec id="article-37573.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fluticasone is a corticosteroid with a direct local effect of vasoconstriction and anti-inflammatory activity. Glucocorticoids inhibit the initial inflammatory events such as vasodilation, vascular permeability, and leukocyte emigration.<xref ref-type="bibr" rid="article-37573.r9">[9]</xref><xref ref-type="bibr" rid="article-37573.r10">[10]</xref>&#x000a0;Fluticasone directly decreases inflammatory cells such as eosinophils, monocytes, mast cells, macrophages, and dendritic cells. This drug reduces the number of these cells and also the number of cytokines they produce. This medication also directly increases &#x003b2;-2 receptors on airway smooth muscle and decreases mucus gland secretions.<xref ref-type="bibr" rid="article-37573.r10">[10]</xref>&#x000a0;This corticosteroid also increases the anti-inflammatory effects of annexin-1, secretory leukoprotease inhibitor (SLPI),&#x000a0;mitogen-activated kinase phosphatase-1 (MKP-1), glucocorticoid-induced leucine zipper protein (GILZ), and I-kappa B-alpha&#x000a0;and inhibitor of NF-kappa B.<xref ref-type="bibr" rid="article-37573.r10">[10]</xref>&#x000a0;Clinicians must distinguish between different formulations of fluticasone, including fluticasone furoate and&#x000a0;propionate. Fluticasone furoate has high lipophilicity, high tissue permeability, low solubility, and slow dissolution of inhaled drug particles. Only about half the quantity of fluticasone furoate is needed to occupy the same number of glucocorticoid receptors&#x000a0;as&#x000a0;fluticasone propionate.<xref ref-type="bibr" rid="article-37573.r11">[11]</xref><xref ref-type="bibr" rid="article-37573.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Fluticasone propionate's systemic bioavailability after oral inhalation is low. Similar to fluticasone propionate, fluticasone furoate is also administered via inhalation. Topical absorption of fluticasone propionate is&#x000a0;influenced by factors such as the formulation vehicle and the integrity of the epidermal barrier. Occlusive dressings enhance the penetration of fluticasone through the skin.&#x000a0;According to the "Key Potentially Inappropriate Drugs in Pediatrics" (KIDs List), topical corticosteroids of medium, high, and very high potency may lead to adrenal suppression and potentially have a higher rate of systemic absorption in children compared to adults. Avoiding their use in infants younger than&#x000a0;1 year is recommended, particularly for conditions including diaper dermatitis.<xref ref-type="bibr" rid="article-37573.r13">[13]</xref></p>
        <p><bold>Distribution:</bold> Both fluticasone propionate and fluticasone furoate exhibit high levels of protein binding in serum. Fluticasone propionate and fluticasone furoate are typically about 99% protein-bound. Fluticasone propionate has a volume of distribution of 4.2 liters per kilogram (L/kg), while fluticasone furoate has a volume of distribution of 661 L.</p>
        <p><bold>Metabolism:</bold> Both fluticasone propionate and fluticasone furoate undergo extensive first-pass metabolism in the liver, primarily mediated by the enzyme cytochrome 3A4 (CYP3A4).<xref ref-type="bibr" rid="article-37573.r14">[14]</xref></p>
        <p><bold>Excretion:</bold> Both fluticasone propionate and fluticasone furoate are primarily eliminated through fecal excretion, with a smaller portion excreted in the urine. Regarding cortisol suppression, the differences observed between fluticasone propionate and fluticasone furoate mainly stem from potency&#x000a0;differences.<xref ref-type="bibr" rid="article-37573.r15">[15]</xref></p>
      </sec>
      <sec id="article-37573.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Fluticasone has received FDA approval for oral inhalational, nasal, and topical formulations.</p>
        <p>
<bold>Oral Inhalation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluticasone propionate aerosol inhalation, in a metered-dose inhaler format, is available in strengths of 44 &#x003bc;g/actuation, 110 &#x003bc;g/actuation, or 220 &#x003bc;g/actuation.</p>
          </list-item>
          <list-item>
            <p>Fluticasone propionate is offered as a breath-activated aerosol powder inhaler in strengths of 50 &#x003bc;g/actuation, 100 &#x003bc;g/actuation, or 250 &#x003bc;g/actuation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Fluticasone furoate is available as a breath-activated aerosol powder inhaler in strengths of 50 &#x003bc;g/actuation, 100 &#x003bc;g/actuation, or 200 &#x003bc;g/actuation.</p>
          </list-item>
          <list-item>
            <p>The oral medication can be given via a dry powder inhaler, a metered-dose inhaler, or a swallowed form. The dry powder should be administered roughly the same time daily, and after inhalation, the patient should rinse their mouth and spit out the water to avoid oral thrush.&#x000a0;Patients should shake the canister and spray upon inhalation to receive accurate medication from the metered inhaler. No spacer should be used for the dry powder, but it is an option for the metered-dose inhaler. The swallowed form, only for eosinophilic esophagitis,&#x000a0;is sprayed into the pharynx and swallowed. The patient should not eat or drink for 30 minutes following administration.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients who take fluticasone have a higher incidence of oral thrush than those taking beclomethasone.<xref ref-type="bibr" rid="article-37573.r16">[16]</xref>&#x000a0;This increase correlates with dosage, as<italic toggle="yes">&#x000a0;</italic>candidiasis&#x000a0;rises with increasing fluticasone dosage. Gargling with amphotericin B is an effective treatment for fluticasone-associated thrush.<xref ref-type="bibr" rid="article-37573.r16">[16]</xref>&#x000a0;Fluconazole-resistant candidiasis has also been successfully treated with a combination of fluconazole plus terbinafine therapy.<xref ref-type="bibr" rid="article-37573.r17">[17]</xref> Patients are encouraged to gargle with water immediately after using the inhaler as a preventive measure to reduce the incidence of candidiasis.<xref ref-type="bibr" rid="article-37573.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Nasal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The nasal spray should be used regularly. The bottle should be shaken gently before each use. While keeping the bottle upright, one nostril should be plugged and the pump pressed to release spray into the other nostril. The&#x000a0;patient should inhale deeply through the nose during the medication's spraying.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Conventional fluticasone furoate nasal suspension is available in a nasal formulation containing 27.5 &#x003bc;g per spray.</p>
          </list-item>
          <list-item>
            <p>Fluticasone propionate nasal spray is provided at a strength of 50 &#x003bc;g per actuation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The novel fluticasone propionate nasal spray delivers 93 &#x003bc;g of fluticasone propionate per actuation. Before the initial use, it is necessary to prime the fluticasone propionate nasal spray with the exhalation delivery system by gently shaking the bottle and pressing it 7 times or until a fine mist appears. The spray&#x000a0;should be directed into the air, away from the face. If the nasal spray has not been used for 7 days or longer, it should be primed again by shaking and releasing&#x000a0;2 sprays in the air, away from the face. To administer the fluticasone propionate nasal spray, insert the tip of the cone-shaped nosepiece deeply into one nostril, creating a secure seal. Then, the flexible mouthpiece is placed into the mouth, ensuring a tight seal with the nostril. While blowing into the mouthpiece, the bottle is pressed to activate the spray pump. Maintaining continuous blowing through the mouth during this process is crucial for proper drug deposition. The process should be repeated in the other nostril to complete the dose.&#x000a0;The delivery system&#x000a0;is FDA-approved for chronic rhinosinusitis with/without nasal polyposis.<xref ref-type="bibr" rid="article-37573.r19">[19]</xref><xref ref-type="bibr" rid="article-37573.r8">[8]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Topical</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluticasone propionate is available in cream (0.05%) and&#x000a0;ointment (0.005%) formulations.</p>
          </list-item>
          <list-item>
            <p>A thin layer of fluticasone propionate should be applied and rubbed into the skin. Contact with the eyes should be avoided, and this medication should not be used on the face, armpits, or groin unless directed otherwise.</p>
          </list-item>
          <list-item>
            <p>Fluticasone is applied topically once daily every 12 hours for atopic dermatitis and dermatosis. If no improvements are observed within&#x000a0;2 weeks of consistent use, reassess the diagnosis.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The product&#x000a0;labeling does not specify dosage adjustments for adult hepatic impairment. However, caution is advised in moderate to severe impairment, as fluticasone is extensively metabolized in the liver.</p>
        <p><bold>Renal impairment: </bold>There is no requirement to adjust the fluticasone dosage for renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Fluticasone was previously classified as a category C medication by the FDA regarding its safety during pregnancy. Recent evidence indicates potential safety advantages for pregnant individuals. Fluticasone may be considered an option for managing rhinitis during pregnancy due to its favorable safety profile.<xref ref-type="bibr" rid="article-37573.r20">[20]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>The amount of inhaled corticosteroids transferred to breast milk is not precisely known; it is minimal and unlikely to harm a breastfeeding baby. Expert opinion supports using inhaled, nasal, and oral corticosteroids during breastfeeding.<xref ref-type="bibr" rid="article-37573.r21">[21]</xref>&#x000a0;Limited data exist on the safety of topical fluticasone during breastfeeding. However, the risk to a breastfeeding infant from short-term use of topical corticosteroids is considered low, particularly if less potent options are used sparingly. Direct contact between treated areas and the infant's skin be avoided. For nipple eczema, topical corticosteroids can be applied after nursing, with gentle cleaning of the nipples before breastfeeding. Water-based cream or gel products are preferred over ointments to minimize the risk of the baby ingesting mineral paraffin.<xref ref-type="bibr" rid="article-37573.r22">[22]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>According to the "Key Potentially Inappropriate Drugs in Pediatrics" (KIDs List), topical corticosteroids of medium, high, and very high potency may lead to adrenal suppression and potentially have a higher rate of systemic absorption in children compared to adults.&#x000a0;These drugs should&#x000a0;be avoided in infants younger than&#x000a0;1 year, particularly for conditions such as diaper dermatitis.<xref ref-type="bibr" rid="article-37573.r13">[13]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;There&#x000a0;are no noticeable variations in the safety and effectiveness of fluticasone between patients who are 65 and older and younger adults.</p>
      </sec>
      <sec id="article-37573.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse events from fluticasone include:</p>
        <p>
<bold>Local</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dysphonia</p>
          </list-item>
          <list-item>
            <p>Oropharyngeal candidiasis</p>
          </list-item>
          <list-item>
            <p>Cough</p>
          </list-item>
          <list-item>
            <p>Pneumonia&#x000a0;<xref ref-type="bibr" rid="article-37573.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Between 10% and 20% of inhaled corticosteroids make it to the lungs, meaning 80% to 90% go through to the gastrointestinal tract. The liver inactivates much of the medication during its first pass. The amount of drug not inactivated by the liver and the medication absorbed in the lungs are responsible for the systemic effects.<xref ref-type="bibr" rid="article-37573.r10">[10]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Systemic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adrenal suppression</p>
          </list-item>
          <list-item>
            <p>Growth suppression</p>
          </list-item>
          <list-item>
            <p>Bruising</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Cataracts</p>
          </list-item>
          <list-item>
            <p>Glaucoma</p>
          </list-item>
          <list-item>
            <p>Metabolic abnormalities</p>
          </list-item>
          <list-item>
            <p>Psychiatric disturbances&#x000a0;<xref ref-type="bibr" rid="article-37573.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>In patients with asthma, there is a 21% higher risk of severe asthma exacerbation when treated with fluticasone alone compared to those treated with a combination of fluticasone and salmeterol.<xref ref-type="bibr" rid="article-37573.r23">[23]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Fluticasone, a substrate of CYP3A4, interacts with strong inhibitors of this enzyme, such as ritonavir, ketoconazole, and others. Co-administration with these inhibitors is not recommended due to the potential for increased adverse effects. Ritonavir specifically has been shown to significantly elevate plasma fluticasone levels and the risk of systemic adverse effects.<xref ref-type="bibr" rid="article-37573.r24">[24]</xref></p>
      </sec>
      <sec id="article-37573.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with documented hypersensitivity to fluticasone should not take this medication.&#x000a0;Many formulations contain milk proteins or lactose; those with known allergies to these substances should not use this medication.<xref ref-type="bibr" rid="article-37573.r25">[25]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Nasal adverse reactions:</bold> Fluticasone may lead to epistaxis, nasal erosions, ulcerations, and septal perforations. Patients using fluticasone for extended periods should be monitored for changes in nasal mucosa. If septal perforation occurs, fluticasone should be discontinued.</p>
        <p><bold>Immunosuppression and infection:</bold> Fluticasone may increase susceptibility to infections. Caution is advised in patients with active infections or prior corticosteroid treatment.</p>
        <p><bold>Hypercorticism and adrenal suppression:</bold> Fluticasone may cause hypercorticism and adrenal suppression, particularly with prolonged use or higher doses. Patients transitioning from systemic corticosteroid therapy to topical corticosteroids should be closely monitored for acute adrenal insufficiency during stress events. Rapid reductions in systemic corticosteroid dosages may exacerbate symptoms in patients with asthma or other chronic conditions requiring long-term systemic corticosteroid treatment.</p>
        <p><bold>Reduction in bone mineral density:</bold> Long-term use of fluticasone may lead to decreased bone mineral density. Patients&#x000a0;with major risk factors should be monitored for reduced bone mass.</p>
        <p><bold>Acute bronchospasm:</bold> Fluticasone&#x000a0;should be avoided as a primary treatment for acute bronchospasm.<xref ref-type="bibr" rid="article-37573.r26">[26]</xref></p>
      </sec>
      <sec id="article-37573.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients on fluticasone should undergo monitoring for the adverse effects listed above. The practitioner should ask the patient about cough, recent illnesses, bruising, changes to mood, and vision disturbances. Providers should monitor for signs of hippocampus-pituitary-adrenal axis suppression and oral candidiasis. Pulmonary function tests (PFT) and DEXA scans may be useful in patients with complaints associated with new breathing changes and signs of osteoporosis.</p>
        <p>Slowed growth in children and reduced mineral density are problematic effects of inhaled corticosteroids. Studies show that the decreased growth was permanent in children who used budesonide. The effect was long-lasting for those who used fluticasone but not permanent.<xref ref-type="bibr" rid="article-37573.r27">[27]</xref>&#x000a0;Reduced bone density in children was only associated with high dose inhaled corticosteroids (ICS). Children&#x02019;s growth should be monitored every 3 to 6 months, and those taking high-dose ICS should have their bone mineral density monitored yearly.<xref ref-type="bibr" rid="article-37573.r27">[27]</xref></p>
      </sec>
      <sec id="article-37573.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is documentation of substantial lactic acidosis after an overdose of inhaled salmeterol and fluticasone.<xref ref-type="bibr" rid="article-37573.r28">[28]</xref>&#x000a0;The patient inhaled 60 puffs of the combination medication in a suicide attempt and presented with sympathomimetic syndrome, metabolic acidosis, and hyperlactatemia. She received supportive therapy and was within normal health limits the following day.<xref ref-type="bibr" rid="article-37573.r28">[28]</xref> This clinical presentation was likely due to the salmeterol being more than the fluticasone, which lent support to the idea that fluticasone is a relatively safe medication.</p>
      </sec>
      <sec id="article-37573.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Research has revealed that inhaled corticosteroids cross the placenta. However, research has found no significant association between ICS and congenital organ malformations.<xref ref-type="bibr" rid="article-37573.r29">[29]</xref> There have been documented risks to the fetus with maternal asthma exacerbations. The risk-benefit ratio should be a consideration when prescribing ICS to pregnant women.<xref ref-type="bibr" rid="article-37573.r29">[29]</xref>&#x000a0;A 6-month observational study found that&#x000a0;older&#x000a0;patients had a sustained improved knowledge and use of inhalers when educated by an on-staff pharmacist.<xref ref-type="bibr" rid="article-37573.r30">[30]</xref> Optimizing user techniques eventually provides them with the most medication possible per administration. They are more likely to receive benefits and symptom resolution and less likely to change medications when receiving their prescribed dose. Working with pharmacists to provide new and old inhaler users with administration techniques will increase their medication satisfaction and health outcomes.<xref ref-type="bibr" rid="article-37573.r30">[30]</xref></p>
        <p>Another study assessed the effect of pretreatment with fluticasone for&#x000a0;6 weeks before seasonal allergen provocation; this was a double-blind, placebo-controlled study. They found significant histologic changes after&#x000a0;4 weeks of treatment with 200 mg of fluticasone twice daily.<xref ref-type="bibr" rid="article-37573.r31">[31]</xref> There were fewer epithelial Langerhans cells, mast cells, T-cells, macrophages, and eosinophils in the nasal mucosa of those who received fluticasone than the placebo group. Cellular influx after allergen exposure was also significantly decreased in this group after&#x000a0;4 weeks of treatment. Fluticasone demonstrated effectiveness in early and late-phase allergic rhinitis.<xref ref-type="bibr" rid="article-37573.r31">[31]</xref>&#x000a0;Healthcare practitioners should advise prompt prophylactic fluticasone treatment for patients with allergic nasal symptoms. Since fluticasone is now available in the USA as an over-the-counter medication, health practitioners should work in an interprofessional team to ensure compliance and proper use; this collaborative team approach includes physicians, nurses, and pharmacists, communicating across disciplines to ensure optimal therapeutic outcomes while minimizing adverse effects and patient risk.</p>
      </sec>
      <sec id="article-37573.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37573&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37573">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37573/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37573">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37573.s11">
        <title>References</title>
        <ref id="article-37573.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noseda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Drug therapies of COPD].</article-title>
            <source>Rev Med Brux</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>A354</fpage>
            <page-range>A354-7</page-range>
            <pub-id pub-id-type="pmid">14606301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tho</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>VTT</given-names>
              </name>
              <name>
                <surname>Dung</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Phu</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Dinh-Xuan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>LTT</given-names>
              </name>
            </person-group>
            <article-title>GINA Implementation Improves Asthma Symptoms Control and Lung Function: A Five-Year Real-World Follow-Up Study.</article-title>
            <source>J Pers Med</source>
            <year>2023</year>
            <month>May</month>
            <day>10</day>
            <volume>13</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37240979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seidman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gurgel</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hackell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ishman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Krouse</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Malekzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mims</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Omole</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <collab>Guideline Otolaryngology Development Group. AAO-HNSF</collab>
            </person-group>
            <article-title>Clinical practice guideline: Allergic rhinitis.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>152</volume>
            <issue>1 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-43</page-range>
            <pub-id pub-id-type="pmid">25644617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fokkens</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hellings</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reitsma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toppila-Salmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernal-Sprekelsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mullol</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alobid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Terezinha Anselmo-Lima</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bachert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>von Buchwald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cervin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Constantinidis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Gabory</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Desrosiers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diamant</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Gevaert</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Hafner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Joos</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Kalogjera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Knill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kocks</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Limpens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebeer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lourenco</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Meco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matricardi</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>O'Mahony</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Philpott</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Senior</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Teeling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tomazic</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Agius</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ahlstrom-Emanuelsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alabri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Albu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhabash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aleksic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aloulah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Qudah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alsaleh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baban</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baudoin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balvers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Battaglia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedoya</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Beule</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bofares</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brozek-Madry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Callejas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caulley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chussi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Corso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Coste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Hadi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Elfarouk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eloy</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Farrokhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Felisati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Fishchuk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Goncalves</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Grdinic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grgic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hamizan</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Heinichen</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ping</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Ivaska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jakimovska</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jovancevic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kakande</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karpischenko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kariyawasam</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kawauchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klimek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krzeski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kopacheva Barsova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Letort</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lopatin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahdjoubi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mesbahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Netkovski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nyenbue Tshipukane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Obando-Valverde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onerci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Otori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ouennoughy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozkan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peric</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plzak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prokopakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prepageran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Psaltis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pugin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raftopulos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rombaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riechelmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sahtout</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarafoleanu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Searyoh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shkoukani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shukuryan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sicak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sindvongs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soklic Kosak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stjarne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sutikno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steinsvag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tantilipikorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thanaviratananich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Urbancic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valiulius</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vasquez de Aparicio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vicheva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virkkula</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Voegels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagenmann</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wardani</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Welge-Lussen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Witterick</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zabolotniy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zsolt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zwetsloot</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>European Position Paper on Rhinosinusitis and Nasal Polyps 2020.</article-title>
            <source>Rhinology</source>
            <year>2020</year>
            <month>Feb</month>
            <day>20</day>
            <volume>58</volume>
            <issue>Suppl S29</issue>
            <fpage>1</fpage>
            <page-range>1-464</page-range>
            <pub-id pub-id-type="pmid">32077450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brazzini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2002</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-58</page-range>
            <pub-id pub-id-type="pmid">11817968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gorski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Ramalingam</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers.</article-title>
            <source>J Asthma Allergy</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>667</fpage>
            <page-range>667-677</page-range>
            <pub-id pub-id-type="pmid">37409000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilgili</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Durmaz</surname>
                <given-names>H&#x000d6;</given-names>
              </name>
              <name>
                <surname>Dilber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Topical Azelastine and Fluticasone Dipropionate Combination in Children With Adenoid Hypertrophy.</article-title>
            <source>Ear Nose Throat J</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-34</page-range>
            <pub-id pub-id-type="pmid">36053218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Adappa</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Mahdavinia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sindwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2).</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>1049</fpage>
            <page-range>1049-1061</page-range>
            <pub-id pub-id-type="pmid">38244014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coutinho</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.</article-title>
            <source>Mol Cell Endocrinol</source>
            <year>2011</year>
            <month>Mar</month>
            <day>15</day>
            <volume>335</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-13</page-range>
            <pub-id pub-id-type="pmid">20398732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Inhaled Corticosteroids.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Mar</month>
            <day>08</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>514</fpage>
            <page-range>514-540</page-range>
            <pub-id pub-id-type="pmid">27713266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prabhudesai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Jadhav</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Bhagat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barkate</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e34825</fpage>
            <pub-id pub-id-type="pmid">36919064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley-Yates</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids: potency, dose equivalence and therapeutic index.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-80</page-range>
            <pub-id pub-id-type="pmid">25808113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellinga</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title><italic>K</italic>ey Potentially <italic>I</italic>nappropriate <italic>D</italic>rugs in Pediatrics: The KIDs List.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-191</page-range>
            <pub-id pub-id-type="pmid">32265601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meakleartmongkol</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tangpanithandee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanavivit</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jiso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pongchaikul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirdlarp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khemawoot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nathisuwan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases.</article-title>
            <source>PLoS One</source>
            <year>2023</year>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>e0293866</fpage>
            <pub-id pub-id-type="pmid">37972000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley-Yates</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Deans</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.</article-title>
            <source>Pulm Pharmacol Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>77</volume>
            <fpage>102171</fpage>
            <pub-id pub-id-type="pmid">36243386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukushima</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matsuse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tomari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obase</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>646</fpage>
            <page-range>646-51</page-range>
            <pub-id pub-id-type="pmid">12839324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghannoum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.</article-title>
            <source>Clin Diagn Lab Immunol</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>921</fpage>
            <page-range>921-3</page-range>
            <pub-id pub-id-type="pmid">10548586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hejazi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shafiifar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mashayekhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sattari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Proper Usage of Glucocorticosteroid Inhalers and Their Adverse Effects in Asthmatic Patients.</article-title>
            <source>Tanaffos</source>
            <year>2016</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-16</page-range>
            <pub-id pub-id-type="pmid">27403173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Sindwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leopold</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-41</page-range>
            <pub-id pub-id-type="pmid">35674488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Amrol</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dinakar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>DES</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <collab>Chief Editor(s):</collab>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <collab>Joint Task Force on Practice Parameters:</collab>
              <name>
                <surname>Dinakar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <collab>Workgroup Contributors:</collab>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Amrol</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hagan</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>DES</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Rhinitis 2020: A&#x000a0;practice parameter update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>146</volume>
            <issue>4</issue>
            <fpage>721</fpage>
            <page-range>721-767</page-range>
            <pub-id pub-id-type="pmid">32707227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Fluticasone, Topical</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Fluticasone, Inhaled</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stempel</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Raphiou</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Kral</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Yeakey</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Emmett</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Prazma</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Buaron</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Pascoe</surname>
                <given-names>SJ</given-names>
              </name>
              <collab>AUSTRI Investigators</collab>
            </person-group>
            <article-title>Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>May</month>
            <day>12</day>
            <volume>374</volume>
            <issue>19</issue>
            <fpage>1822</fpage>
            <page-range>1822-30</page-range>
            <pub-id pub-id-type="pmid">26949137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arrington-Sanders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hutton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siberry</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1044</fpage>
            <page-range>1044-8</page-range>
            <pub-id pub-id-type="pmid">17072128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Motheral</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reaction after inhalation of a lactose-containing dry powder inhaler.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-11</page-range>
            <pub-id pub-id-type="pmid">25309152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sher</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sakov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caracta</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2017</year>
            <month>Sep</month>
            <day>21</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-353</page-range>
            <pub-id pub-id-type="pmid">28639542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skoner</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids: Effects on growth and bone health.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>595</fpage>
            <page-range>595-600</page-range>
            <pub-id pub-id-type="pmid">27979015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vanpee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thys</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone.</article-title>
            <source>CJEM</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>378</fpage>
            <page-range>378-81</page-range>
            <pub-id pub-id-type="pmid">23131487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alhussien</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Alhedaithy</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Alsaleh</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Safety of intranasal corticosteroid sprays during pregnancy: an updated review.</article-title>
            <source>Eur Arch Otorhinolaryngol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>275</volume>
            <issue>2</issue>
            <fpage>325</fpage>
            <page-range>325-333</page-range>
            <pub-id pub-id-type="pmid">29164323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouwmeester</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bungay</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Optimizing inhaler use by pharmacist-provided education to community-dwelling elderly.</article-title>
            <source>Respir Med</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>109</volume>
            <issue>10</issue>
            <fpage>1363</fpage>
            <page-range>1363-8</page-range>
            <pub-id pub-id-type="pmid">26341546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37573.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleinjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Severijnen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Boks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fokkens</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>107</volume>
            <issue>4</issue>
            <fpage>627</fpage>
            <page-range>627-33</page-range>
            <pub-id pub-id-type="pmid">11295650</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
